Fibroscan

Written by: Alan Franciscus, Editor-in-Chief

FORWARD

In 2013 the Food and Drug Administration (FDA) cleared Fibroscan for marketing. Fibroscan is based on ultrasound elastography technology using a machine that sends a vibration wave through the liver. The Fibroscan will measure how long it takes for the wave to travel through the liver. It has been tested extensively in people with hepatitis C.

While the Fibroscan isn't 100% accurate, it is has been shown to have a high degree of accuracy for predicting mild fibrosis, severe fibrosis and cirrhosis. It is less likely to distinguish the difference between no or minimal fibrosis. It is also been shown to be less accurate in people who are obese, and in those who have bile duct damage or ascites (accumulation of fluid in the abdominal cavity). Although not 100% accurate there have been studies that have found that combining the Fibroscan and Fibrometer—a blood test that measures hyaluronate, prothrombin time, platelets, AST, a2 macroglobulin, urea, and age—can provide a very high degree of accuracy.

The actual procedure is painless. A gel is deposited on the skin where the Fibroscan probe will be pressed (in the location of the liver) and multiple readings are taken. Once the procedure is completed the machine will take an average of all of the readings.

The advantages of the Fibroscan vs. the percutaneous or needle biopsy include:

- Fibroscan is a patient friendly and anxiety-free procedure especially compared to a needle biopsy.
- Relatively quick and simple procedure that can be performed more frequently and in an outpatient setting.

—CONTINUED

HCSP FACT SHEET

A publication of the Hepatitis C Support Project

EXECUTIVE DIRECTOR, EDITOR-IN-CHIEF, HCSP PUBLICATIONS

Alan Franciscus

DESIGN

Leslie Hoex, Blue Kangaroo Design

PRODUCTION

Leslie Hoex

CONTACT INFORMATION

Hepatitis C Support Project PO Box 15144 Sacramento, CA 95813 alanfranciscus@ hcvadvocate.org

The information in this fact sheet is designed to help you understand and manage HCV and is not intended as medical advice. All persons with HCV should consult a medical practitioner for diagnosis and treatment of HCV.

This information is provided by the Hepatitis C Support Project a nonprofit organization for HCV education, support and advocacy

Reprint permission is granted and encouraged with credit to the Hepatitis C Support Project.

Fibroscan —CONTINUED FROM PAGE 1

• It is safe for people who have a risk of bleeding (people with bleeding disorders, people with low platelets, etc.).

The price of the procedure varies, but since it is FDA approved and there is less of a chance of complications, medical insurance companies should cover some or all of the costs. Be sure to check out this page on Fibroscan at HepCBC http://hepcbc.ca/fibroscan-alternative-to-biopsy/ and this informative video on Youtube: www.youtube.com/watch?v=l E4ZGmKooA

Related publications:

An Overview of HCV Diagnostic Tests

www.hcvadvocate.org/hepatitis/factsheets_pdf/diagnostic.pdf

HCV Genotype, Quasispecies and Subtype

http://hcvadvocate.org/hepatitis/factsheets_pdf/genotype.pdf

Viral Load Test

http://hcvadvocate.org/hepatitis/factsheets_pdf/viralload.pdf

For more information

- Centers for Disease Control and Prevention www.cdc.gov/Hepatitis
- Mayo Clinic: <u>www.mayoclinic.com/health/</u> liver-biopsy/MY00949
- MedlinePlus:
 <u>www.nlm.nih.gov/medlineplus</u>
 encv/article/003895.htm
- National Digestive Diseases Information Clearinghouse (NDDIC)
 http://digestive.niddk.nih.gov/ddiseases/pubs/liverbiopsy/



A GUIDE TO UNDERSTANDING HCV 2016

We have updated our most popular publication to include information for 2016.

Please feel free to download, read, print and distribute.

DOWNLOAD

http://hcvadvocate.org/hepatitis/factsheets_pdf/HCV_Guide.pdf

